BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Boehringer Ingelheim
QuintilesIMS
Chinese Patent Office
Fish and Richardson
Merck
Johnson and Johnson
US Army
Fuji
McKesson

Generated: January 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,759,359

« Back to Dashboard

Summary for Patent: 7,759,359
Title:Method of treating bladder dysfunction with once-a-day trospium salt formulation
Abstract:A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C.sub.min) and maximum (C.sub.max) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
Inventor(s): Kidane; Argaw (Montgomery Village, MD), Flanner; Henry H. (Montgomery Village, MD), Bhatt; Padmanabh (Rockville, MD), Raoufinia; Arash (McLean, VA)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:11/889,964
Patent Claims: 1. A method for treating a bladder dysfunction in a patient comprising orally administering to a patient suffering from a bladder dysfunction a once-a-day dosage formulation of a pharmaceutically acceptable salt of trospium (Tr.sup.+) comprising at least one component selected from the group consisting of an extended release (XR) and a delayed release (DR) component; wherein at least a portion of said formulation releases trospium chloride in the lower gastrointestinal (GI) tract; which formulation provides an average Cmax at steady state of less than 2400 pg/ml of Tr.sup.+ at a Tmax of less than 6 hours; and wherein the bladder dysfunction is selected from the group consisting of urinary frequency, urgency, nocturia, urge-incontinence associated with detrusor instability, urge syndrome, and detrusor hyperreflexia.

2. The method of claim 1 in which the pharmaceutically acceptable salt of trospium is selected from the group consisting of a fluoride, chloride, bromide and iodide salt of trospium.

3. The method of claim 1 in which the pharmaceutically acceptable salt of trospium is trospium chloride.

4. The method of claim 1 which produces fewer incidents of one or more side effects, selected from the group of dry mouth, headache, constipation, dyspepsia, and abdominal pain, compared with the number of incidents of said one or more side effects observed after oral, twice daily administration of a 20 mg immediate release dosage formulation of trospium chloride.

5. The method of claim 1 in which said once-a-day formulation includes a mixture of a delayed release (DR) component and an extended release (XR) component.

6. The method of claim 5 in which the DR component and XR component each includes 30 mg of trospium chloride.

7. A method for treating a bladder dysfunction in a patient comprising orally administering to a patient suffering from a bladder dysfunction a once-a-day dosage formulation of a pharmaceutically acceptable salt of trospium (Tr.sup.+), comprising at least one component selected from the group consisting of an extended release (XR) and a delayed release (DR) component, wherein at least a portion of said formulation releases trospium chloride in the lower gastrointestinal (GI) tract; which formulation provides an average Cmax at steady state of less than 2400 pg/ml of Tr.sup.+ at a Tmax of less than 6 hours and which average steady state blood levels of Tr.sup.+ do not fall below 500 pg/ml; and wherein the bladder dysfunction is selected from the group consisting of urinary frequency, urgency, nocturia, urge-incontinence associated with detrusor instability, urge syndrome, and detrusor hyperreflexia.

8. The method of claim 7 in which the pharmaceutically acceptable salt of trospium is selected from the group consisting of a fluoride, chloride, bromide and iodide salt of trospium.

9. The method of claim 7 in which the pharmaceutically acceptable salt of trospium is trospium chloride.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Julphar
US Department of Justice
Chubb
Citi
Merck
Queensland Health
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot